These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

837 related items for PubMed ID: 18414186

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42. Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion.
    Kappelle PJ, van Tol A, Wolffenbuttel BH, Dullaart RP.
    Cardiovasc Ther; 2011 Dec; 29(6):e89-99. PubMed ID: 20645987
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Effects of cholesteryl ester transfer protein inhibitors on human lipoprotein metabolism: why have they failed in lowering coronary heart disease risk?
    Schaefer EJ.
    Curr Opin Lipidol; 2013 Jun; 24(3):259-64. PubMed ID: 23652567
    [Abstract] [Full Text] [Related]

  • 46. Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib.
    Cannon CP, Dansky HM, Davidson M, Gotto AM, Brinton EA, Gould AL, Stepanavage M, Liu SX, Shah S, Rubino J, Gibbons P, Hermanowski-Vosatka A, Binkowitz B, Mitchel Y, Barter P, DEFINE investigators.
    Am Heart J; 2009 Oct; 158(4):513-519.e3. PubMed ID: 19781408
    [Abstract] [Full Text] [Related]

  • 47. Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: Where are we now?
    Barter P, Rye KA.
    Trends Pharmacol Sci; 2011 Dec; 32(12):694-9. PubMed ID: 22088767
    [Abstract] [Full Text] [Related]

  • 48. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia.
    Kastelein JJ, van Leuven SI, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ, Revkin JH, Grobbee DE, Riley WA, Shear CL, Duggan WT, Bots ML, RADIANCE 1 Investigators.
    N Engl J Med; 2007 Apr 19; 356(16):1620-30. PubMed ID: 17387131
    [Abstract] [Full Text] [Related]

  • 49. Is raising HDL a futile strategy for atheroprotection?
    Joy T, Hegele RA.
    Nat Rev Drug Discov; 2008 Feb 19; 7(2):143-55. PubMed ID: 18239670
    [Abstract] [Full Text] [Related]

  • 50. Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans.
    Millar JS, Brousseau ME, Diffenderfer MR, Barrett PH, Welty FK, Faruqi A, Wolfe ML, Nartsupha C, Digenio AG, Mancuso JP, Dolnikowski GG, Schaefer EJ, Rader DJ.
    Arterioscler Thromb Vasc Biol; 2006 Jun 19; 26(6):1350-6. PubMed ID: 16574893
    [Abstract] [Full Text] [Related]

  • 51. Torcetrapib/atorvastatin combination therapy.
    Bays H, McKenney J, Davidson M.
    Expert Rev Cardiovasc Ther; 2005 Sep 19; 3(5):789-820. PubMed ID: 16181026
    [Abstract] [Full Text] [Related]

  • 52. The pharmacology and off-target effects of some cholesterol ester transfer protein inhibitors.
    Vergeer M, Stroes ES.
    Am J Cardiol; 2009 Nov 16; 104(10 Suppl):32E-8E. PubMed ID: 19895942
    [Abstract] [Full Text] [Related]

  • 53. Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits.
    Morehouse LA, Sugarman ED, Bourassa PA, Sand TM, Zimetti F, Gao F, Rothblat GH, Milici AJ.
    J Lipid Res; 2007 Jun 16; 48(6):1263-72. PubMed ID: 17325387
    [Abstract] [Full Text] [Related]

  • 54. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation).
    Nicholls SJ, Tuzcu EM, Brennan DM, Tardif JC, Nissen SE.
    Circulation; 2008 Dec 09; 118(24):2506-14. PubMed ID: 19029466
    [Abstract] [Full Text] [Related]

  • 55. Efficacy, safety, tolerability, and pharmacokinetic profile of evacetrapib administered as monotherapy or in combination with atorvastatin in Japanese patients with dyslipidemia.
    Teramoto T, Takeuchi M, Morisaki Y, Ruotolo G, Krueger KA.
    Am J Cardiol; 2014 Jun 15; 113(12):2021-9. PubMed ID: 24786356
    [Abstract] [Full Text] [Related]

  • 56. HDL-cholesterol: is it really good? Differences between apoA-I and HDL.
    Santos-Gallego CG, Ibanez B, Badimon JJ.
    Biochem Pharmacol; 2008 Aug 15; 76(4):443-52. PubMed ID: 18547543
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Identification of a novel, non-tetrahydroquinoline variant of the cholesteryl ester transfer protein (CETP) inhibitor torcetrapib, with improved aqueous solubility.
    Kalgutkar AS, Frederick KS, Hatch HL, Ambler CM, Perry DA, Garigipati RS, Chang GC, Lefker BA, Clark RW, Morehouse LA, Francone O, Hu X.
    Xenobiotica; 2014 Jul 15; 44(7):591-605. PubMed ID: 24380613
    [Abstract] [Full Text] [Related]

  • 60. The strange case of Dr HDL and Mr HDL: does a NO's story illuminate the mystery of HDL's dark side uncovered by Dr HDL's drug targeting CETP?
    Duriez P, Bordet R, Berthelot P.
    Med Hypotheses; 2007 Jul 15; 69(4):752-7. PubMed ID: 17376606
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 42.